Gastric intestinal metaplasia
diseaseOn this page
Also known as GIMintestinal metaplasia
Summary
Gastric intestinal metaplasia (MONDO:0100190) is a disease and 72 clinical trials. Top therapeutic interventions include folic acid, pyrvinium, and ursodiol. A subtype of stomach disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 72
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | gastric intestinal metaplasia |
| Mondo ID | MONDO:0100190 |
| ICD-10-CM | K31.A |
| NCIT | C8360 |
| UMLS | C0267187 |
| MedGen | 75629 |
| Is cancer (heuristic) | no |
Also known as: GIM · intestinal metaplasia
Disease family
This is a subtype of stomach disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › stomach disorder › gastric intestinal metaplasia
Related subtypes (18): gastric ulcer, functional gastric disease, Dieulafoy lesion, pylorospasm, cascade stomach, pyloric stenosis, gastric dilatation, stomach diverticulosis, gastritis, gastroesophageal reflux disease, hiatus hernia, stomach polyp, non-hypoproteinemic hypertrophic gastropathy, gastric neoplasm, angiodysplasia of stomach, achlorhydria, gastric duplication, pyloric duplication
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 72.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 61 |
| PHASE4 | 6 |
| PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06610266 | PHASE4 | RECRUITING | Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia |
| NCT06610760 | PHASE4 | RECRUITING | Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia |
| NCT07129460 | PHASE4 | NOT_YET_RECRUITING | Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia |
| NCT02534818 | PHASE4 | UNKNOWN | Different Fluorescein Sodium Dosage for the Detection of Gastric Intestinal Metaplasia |
| NCT02930616 | PHASE4 | UNKNOWN | A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized，Cross-over Study |
| NCT05288153 | PHASE4 | COMPLETED | Metformin Efficacy and Safety for Gastric Intestinal Metaplasia |
| NCT06590454 | PHASE2 | RECRUITING | REVerse Intestinal Metaplasia in the Stomach (REVISE) |
| NCT01614418 | PHASE1/PHASE2 | COMPLETED | Radiofrequency Ablation for Gastric Metaplasia and Dysplasia |
| NCT02794428 | PHASE2 | COMPLETED | Chemoprevention of Gastric Carcinogenesis |
| NCT01398579 | PHASE1 | UNKNOWN | Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy |
| NCT02806115 | PHASE1 | UNKNOWN | The Efficacy of Severe Whitening and Delayed Fading in Acetic Acid-enhanced Endoscopy for Diagnosing Gastric Intestinal Metaplasia |
| NCT03250091 | Not specified | RECRUITING | Surveillance of Patients With Precancerous Lesions of the Stomach |
| NCT03554356 | Not specified | ACTIVE_NOT_RECRUITING | Nitrous Oxide For Endoscopic Ablation of Refractory Barrett’s Esophagus (NO FEAR-BE) |
| NCT04613570 | Not specified | RECRUITING | SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up |
| NCT04840056 | Not specified | RECRUITING | Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis |
| NCT05021029 | Not specified | ENROLLING_BY_INVITATION | UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study |
| NCT05053945 | Not specified | RECRUITING | Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study |
| NCT05657080 | Not specified | RECRUITING | Cytosponge for Gastric Intestinal Metaplasia |
| NCT05818072 | Not specified | RECRUITING | The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE |
| NCT06370143 | Not specified | RECRUITING | A Study Collecting Health Information to Understand and Prevent Gastric Cancer |
| NCT07208864 | Not specified | NOT_YET_RECRUITING | Efficacy of an AI System in Training Endoscopists to Assess Gastric Intestinal Metaplasia Via the EGGIM Score |
| NCT07346521 | Not specified | RECRUITING | Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett’s Mucosa During Screening Colonoscopy |
| NCT07542652 | Not specified | RECRUITING | Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis |
| NCT07605312 | Not specified | NOT_YET_RECRUITING | AI-Based Risk Prediction Model for Upper Digestive Tract Cancer |
| NCT01024621 | Not specified | COMPLETED | Confocal Laser Endomicroscopy for the Detection of Gastric Intestinal Metaplasia: a Randomized Controlled Trial |
| NCT01373125 | Not specified | COMPLETED | Is the Neosquamous Epithelium Normal Following Endoscopic Ablation of Dysplastic Barrett’s Esophagus? |
| NCT01374074 | Not specified | COMPLETED | Racial Disparity in Barrett’s Esophagus |
| NCT01384201 | Not specified | COMPLETED | Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia |
| NCT01489397 | Not specified | COMPLETED | Magnified Intelligence Chromoendoscopy Plus Probe-based Confocal Laser Endomicroscopy for Gastric Intestinal Metaplasia Diagnosis |
| NCT01490541 | Not specified | UNKNOWN | The Predictive Scores for Gastric Cancer in Gastric Intestinal Metaplasia (GIM) Patient: a Recommendation for Thai Population |
| NCT01491724 | Not specified | UNKNOWN | The Learning Curve of Probe-based Confocal Laser Endomicroscopy (pCLE) Images Interpretation in Gastric Intestinal Metaplasia (GIM) |
| NCT01642797 | Not specified | UNKNOWN | Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma |
| NCT01646528 | Not specified | UNKNOWN | The Value of Black Spots in Diagnosing Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy |
| NCT01787864 | Not specified | COMPLETED | Prevalence of Dysplasia of the Gastric Cardia |
| NCT01824953 | Not specified | COMPLETED | Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years |
| NCT01896310 | Not specified | COMPLETED | New Classification of Stomach Using Probe-based Confocal Laser Endomicroscopy |
| NCT01945177 | Not specified | COMPLETED | RCT: WLE vs. NBI in Upper Gastrointestinal Endoscopy |
| NCT02063932 | Not specified | UNKNOWN | Association Between Confocal Laser Endomicroscopic (CLE) Features and Gastric Mucosal Microbiome |
| NCT02075905 | Not specified | COMPLETED | Stratifying Risk in Barrett’s Esophagus: A Pilot Study for Biomarker-based Patient Management |
| NCT02332213 | Not specified | COMPLETED | Volatile Markers in Digestive Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FOLIC ACID | 4 | 2 |
| PYRVINIUM | 4 | 2 |
| URSODIOL | 4 | 2 |
| ACETIC ACID | 4 | 1 |
| EFLORNITHINE | 4 | 1 |
| METFORMIN | 4 | 1 |
| BLOOD, WHOLE | 3 | 1 |
| EFLORNITHINE, (S)- | 2 | 1 |
| BERBERINE CHLORIDE | 1 | 1 |
| CHEMBL5409583 | 0 | 1 |
| CHEMBL4446459 | 0 | 1 |